

Antiviral drugs

- 1. Adamantane derivatives
- 2. Neuraminidase inhibitors
- 3. Viral replication inhibitors
- 4. Viral proteases inhibitors
- 5. Imunotherapeutics




1. Adamantane derivatives



1-aminotricyklo[3.3.1.1]decane

1-aminoadamantaneamantadinealso antiparkinsonic



1-(aminoethyl)tricyklo[3.3.1.1]decane

1-(1-aminoethyl)adamantane **rimantadine**


against influenza of type A only; ineffective against swine influenza H1N1
mechanism of action: inhibition of replication of influenza virus type A by blocking of transmembrane protein - proton channel M2
namely prophylactic
frequent resistance (M gene mutation)
adverse effects: frequent; sleeplessness, hallucinations, orthostatic hypotension,

depressions, nausea, vomiting

Ion channel M2 of the influenza virus H1N1 2009 (swine influenza)

homotetrameric protein containing an integral transmembrane tetrahelical channel consists of 97 amino acid rests in every unit; every unit contains the C-terminal domain from 54 AA, the transmembrane domain from 19 AA and the extracelullar N-terminal domain from 24 AA
proton-selective channel is controlled by endosomal pH values; it leads endosomal protons into the virion

•this channel is probably fundamental for the life cycle of the virus




В

Interaction of amantadine with proton channel M2 of viruses H5N1 (A) and H1N1 (B)


•adamantane antivirotics are bound to the outside "lipoid pocket" near Trp41 (in addition H-bridge to Asp 44), the molecule acts as an "molecular wedge", which stabilizes close conformation of the channel gate and increases energy barrier for its opening

•blue spots represent sizes or electron clouds of lipophilic fragments of M2 channel which interact with the drug by hydrophobic interactions






Interaction of rimantadine with proton channel M2 of H5N1 (A) and H1N1 (B) viruses





В

Α



Arg *B*45 2. Viral neuraminidase inhibitors

Neuraminidase (sialidase, acyl-neuramidyl hydrolase):

glycoprotein


•glucosidase which cleaves specifically glycoside

bonds $\alpha\mathchar`-2\mathchar`\to\mathchar`-2\mathchar`\to\mathchar`-6$ to galactose


 enzyme cleaving N-acetylneuraminic acid away from more complex oligosaccharides on the cell surface and thus facilitating releasing of virions from the infected cell and their spreading to other cells of host organism

 also acts as a superficial antigen of the influenza virus with principal significance for the immunity response


in mammals and birds, 9 neuraminidase
 serotypes and 16 hemagglutinin serotypes have
 been found up to now (hemagglutinin is also a superficial antigen)



N-acetylneuraminic acid Aceneuramic acid [INN] N-acetylneuraminic acid and 1st experimental neuraminidase inhibitors





N-acetylneuraminic acid Aceneuramic acid [INN]




R = -CH₃ 2-Deoxy-2,3-dehydro-Nacetylneuraminic acid **DANA**

R = -CF₃ 2-Deoxy-2,3-dehydro-Ntrifluoroacetylneuraminic acid **FANA** Viral neuraminidase inhibitors







Relenza[®] inh. plv. dos.

oseltamivir

Tamiflu[®] cps.


 intranasal administration only dimeric and multimeric forms with expected greater activity, longer elimination half-time and greater bioavailability are being developed

peramivir BCX-1812 •i.v. administration •some 3rd phase clinical tests

completed, some proceeds


•effective against H1N1 (swine), not against H5N1 (bird)

•development of forms for i.v. or i.m. administration



A model of binding of zanamivir to the active site of neuraminidase of reconstructed H1N1 virus from 1918 (similar to swine 2009)

3. Inhibitors of replication of RNA viruses



X = 0

1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

ribavirin

broad spectrum including SARS-coronavirus (Severe Acute Respiratory Syndrome)
 known since 1970th

•approved for treatment of HCV (hepatitis C; \pm pegylated interferon) and RSV (respiration syncytial virus) in children

•mechanisms of action: 1. inhibition of inosine-5'-monophosphate dehydrogenase (changes IMP to xanthosine-5'-monophosphate in *de novo* synthesis of GMP)

2. direct interference with transcription and replication

Rebetol[®], Copegus[®]

```
X = NH


viramidin

syn. taribavirin [USAN]


•prodrug, expected lower toxicity (hemolysis), clinical trials of the 3<sup>rd</sup> phase for HCV

completed
```

Mechanism of action of ribavirin



3. Inhibitors of replication of RNA viruses



favipiravir

5-fluoro-3-hydroxypyrazine-2-carboxamide


T-705

•broad spectrum including influenza A, B, C

clinical trials of the 1st and 2nd phases (pharmacokinetics, dose finding for influenza)
mechanism of action: after entering the cell, phosphorylation to monophosphate by phosphoribosyl transferase and further to triphosphate by gell kinase; in this form the drug inhibits RNA-dependent RNA-polymerase


•in vitro very active against H5N1 (bird) and seasonal influenzas

•low toxicity, no cytotoxic effect



zidovudine

azidothymidin, AZT Retrovir[®] 2°, 3°-didehydro-2°, 3°-dideoxythymidine stavudine Zerit[®]



2',3'-dideoxycytidine zalcitabine ddC

Hivid®

R = -H 2',3'-dideoxy-3'-thiacytidine lamivudine 3TC


Epivir®

R = -F 2´,3´-dideoxy-5-fluor-3´-thiacytidin emtricitabine

Emtriva®


treatment of HIV infections

Reverse transcriptase inhibitors Purine derivatives



{(1*R*)-4-[2-amino-6-(cyclopropylamino)-9*H* -purin-9-yl]cyclopent-2-en-1-yl}methanol


abakavir ABC Ziagen[®]






didanosine ddl Videx[®] Nucleotide reverse transcriptase inhibitors

N²



9-(fosfonylmethoxyethyl)adenine adefovir

•originally developed against HIV, in doses which were needed it was nephrotoxic now treatment of HBV (hepatitis B)





adefovir dipivoxil •a prodrug with improved lipophilicity and bioavailability

•prof. Antonín Holý, Inst. of Org. Chem. and Biochem., Prague nominated for Nobel Prize

Nucleotide reverse transcriptase inhibitors

N







(R)-9-[(2-fosfonylethoxy)propyl]adenine tenofovir •against HIV

tenofovir disoproxil fumarate


 clinical studies for HBV and HIV Viread ® tbl., Truvada ® cps. (+ emtricitabin) Inhibitors of DNA polymerase of herpetic viruses •DNA polymerase of *Herpesviridae* family consists of 2 units: the catalytic subunit UL 54 + additive protein UL 44















valganciclovir

nucleoside analogues, guanine derivatives
herpetic infections including HCMV (human cytomegalovirus)
prodrugs – valine esters have improved biological availability

Inhibitors of DNA polymerase of herpetic viruses




penciclovir Vectavir ® drm crm



famciclovircompetitive inhibitorFamciclovir Arrow ® por tbl flm

Inhibitors of DNA polymerase of herpetic viruses



foscarnet Foscarnetum natricum hexahydricum PhEur

CMV retinitis, other herpesviruses, HIV
mechanism of action: inhibits viral DNA polymerase by binding to the diphosphate binding site and by blocking of cleaving of diphosphate away from the triphosphate of terminal nucleoside which is added to the growing DNA chain
blocks also reversal transcriptase

Viral proteases inhibitors

Inhibitors of HCV (hepatitis C virus) NS3 protease

•hepatitis C: 2 – 15 % of the world population are estimated to be infected, WHO: $1.7.10^8$ people (2006)

• 10 - 20 % overcomes the virus, the rest becomes permanent virus hosts, in 10 - 20 %, cirrhosis or liver cancer is developed

•transfer is parenteral, sexual or vertical (mother \rightarrow child)


H₃C

HN

 $\mathcal{I}H_{2}$

•NS3 proteasa umístěna na eN-terminální domén ě NS3 proteinu, považována za důležité místo zásahu, je zodpovědná za intramolekulárn³ štěpení na místě NS3/4A a následné procesy
 •současně narušuje syntézu interferonového regulačního faktoru 3 (IRF-3) hostitele, čímž snižuje imunitní od pověď

MK-7009



LRSKE

interferon $\alpha_{_2}$

Interferoni alfa-2 solutio concentrata ČL 2005

X1 = Lys α_{2a}

X1 = Arg α_{2b}

•protivirová aktivita v průběhu syntézy virové RNA a bílkoviny

•antiproliferační aktivita

•výroba rekombinantní technikou na bakteriích

•též pegylovaný: peginterferon alfa-2a (Pegasys ®) - na N-konci N², N⁶-dikarboxy-Lys esterifikovaný PEG-monomethyletherem